Estrella Immunopharma, Inc.
ESLAW· Nasdaq
Released Mar 17, 2026, after the close
10-K filed Mar 18, 2026, 77 days after period end · 0001213900-26-029357
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2025dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|
| Net Income | -$613.17K | -$135.80K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Estrella Immunopharma, Inc. · CIK 1844417 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 18, 2026 · 77 d after period end